AXSM insider files sale after 82,100 shares sold in 3 months
Rhea-AI Filing Summary
Axsome Therapeutics, Inc. insider filing reports a proposed sale of 13,390 shares of common stock through Goldman Sachs & Co. LLC with an aggregate market value of $1,588,589.60, intended for sale on 10/07/2025. The filing states there are 49,901,487 shares outstanding, and the shares to be sold were acquired on 05/27/2016 as compensation via stock options with a cashless exercise/same-day sale payment.
The notice also discloses multiple insider sales in the prior three months by Herriot Tabuteau: 19,220 shares on 10/06/2025, 27,907 on 09/12/2025, 15,254 on 09/15/2025, and 19,719 on 09/16/2025, totaling 82,100 shares and gross proceeds shown in the filing. The filer affirms no undisclosed material nonpublic information and references Rule 144 procedures.
Positive
- Planned sale documented with broker (Goldman Sachs & Co. LLC) indicating orderly, broker-assisted execution
- Securities were acquired as compensation on 05/27/2016, consistent with ordinary insider liquidity events
Negative
- Substantial recent insider selling: 82,100 shares sold in the past three months, which may increase available float
- No 10b5-1 adoption date provided on the form, leaving uncertainty about reliance on a prearranged trading plan
Insights
Insider selling is ongoing; 13,390 shares planned, 82,100 sold in prior 3 months.
Reported planned sale of 13,390 shares for $1,588,589.60 on 10/07/2025 follows four recent sales totaling 82,100 shares across 09/12/2025–10/06/2025. The shares were originally acquired as compensation on 05/27/2016 and will be sold via a broker, indicating standard liquidity transactions rather than purchases.
Primary dependency is market execution and share count; monitor aggregate insider sales against outstanding 49,901,487 shares for near-term float impact and any further scheduled filings over the next 30 days.
Form 144 disclosure follows Rule 144 mechanics and includes a 10b5-1 attestation clause.
The filing documents the acquisition method (stock options) and a cashless exercise/same-day sale payment, and includes the signature representation that no material nonpublic information is known. The form references Rule 10b5-1 plan adoption or instructions but does not list a plan adoption date in the shown fields.
Given those entries, confirm whether a written trading plan exists and its adoption date if relying on 10b5-1; any plan date would clarify affirmative safe-harbor reliance within the filing record.